Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target
Sarra Smati,Arnaud Polizzi,Anne Fougerat,Sandrine Ellero-Simatos,Yuna Blum,Yannick Lippi,Marion Régnier,Alexia Laroyenne,Marine Huillet,Muhammad Arif,Cheng Zhang,Frederic Lasserre,Alain Marrot,Talal Al Saati,JingHong Wan,Caroline Sommer,Claire Naylies,Aurelie Batut,Celine Lukowicz,Tiffany Fougeray,Blandine Tramunt,Patricia Dubot,Lorraine Smith,Justine Bertrand-Michel,Nathalie Hennuyer,Jean-Philippe Pradere,Bart Staels,Remy Burcelin,Françoise Lenfant,Jean-François Arnal,Thierry Levade,Laurence Gamet-Payrastre,Sandrine Lagarrigue,Nicolas Loiseau,Sophie Lotersztajn,Catherine Postic,Walter Wahli,Christophe Bureau,Maeva Guillaume,Adil Mardinoglu,Alexandra Montagner,Pierre Gourdy,Hervé Guillou
DOI: https://doi.org/10.1136/gutjnl-2020-323323
IF: 24.5
2021-04-26
Gut
Abstract:Objective We evaluated the influence of sex on the pathophysiology of non-alcoholic fatty liver disease (NAFLD). We investigated diet-induced phenotypic responses to define sex-specific regulation between healthy liver and NAFLD to identify influential pathways in different preclinical murine models and their relevance in humans. Design Different models of diet-induced NAFLD (high-fat diet, choline-deficient high-fat diet, Western diet or Western diet supplemented with fructose and glucose in drinking water) were compared with a control diet in male and female mice. We performed metabolic phenotyping, including plasma biochemistry and liver histology, untargeted large-scale approaches (liver metabolome, lipidome and transcriptome), gene expression profiling and network analysis to identify sex-specific pathways in the mouse liver. Results The different diets induced sex-specific responses that illustrated an increased susceptibility to NAFLD in male mice. The most severe lipid accumulation and inflammation/fibrosis occurred in males receiving the high-fat diet and Western diet, respectively. Sex-biased hepatic gene signatures were identified for these different dietary challenges. The peroxisome proliferator-activated receptor α (PPARα) co-expression network was identified as sexually dimorphic, and in vivo experiments in mice demonstrated that hepatocyte PPARα determines a sex-specific response to fasting and treatment with pemafibrate, a selective PPARα agonist. Liver molecular signatures in humans also provided evidence of sexually dimorphic gene expression profiles and the sex-specific co-expression network for PPARα. Conclusions These findings underscore the sex specificity of NAFLD pathophysiology in preclinical studies and identify PPARα as a pivotal, sexually dimorphic, pharmacological target. Trial registration number NCT02390232 .
gastroenterology & hepatology